The problem
Prescribing for depression, schizophrenia or addiction still leans on small trials and clinician instinct: real-world behavioral-health records sit scattered across providers in incompatible formats, so nobody can say at scale which treatments work for which patients.
How it works
Holmusk’s NeuroBlu Database pools de-identified behavioral-health clinical data, structures free-text notes with natural-language processing, and serves AI-powered analytics for outcomes research, cohort building and treatment personalization. A data partnership with Veradigm pipes in cohorts of behavioral-health patients and related clinical data, compounding the asset with every partner added. Digital disease-management programs sit on top for direct patient impact.
Pain points
Fragmented psychiatric records, endpoints that rely on self-report and infrequent visits, and pharma pipelines flying blind on real-world effectiveness — against a post-pandemic surge in demand for mental-health care.
Business model
Enterprise data and analytics deals with pharma, providers and payors, plus strategic investments from data-rich partners (Veradigm) that double as supply agreements for the database itself.
Challenges
Coverage is the moat and the risk: NeuroBlu’s value hinges on partners continuing to contribute cohorts under tightening data-privacy expectations, and enterprise sales cycles in life sciences are long. Pure-play digital-therapeutics rivals compete for the same buyer budgets.
Funding
- Raised: $45M Series B led by Nasdaq-listed Veradigm (announced January 2023) with Heritas Capital, Health Catalyst Capital, Novartis (dRx Capital), Northwell Holdings and other existing investors; earmarked for expanding the NeuroBlu Database.
- Strategic investment: Veradigm added a further $30M strategic investment (reported October 2023), deepening the data partnership.
- Total funding of $106.2M reported by Medical Startups directory.
Latest — October 2023
Veradigm’s $30M strategic investment turned the Series B lead into a long-term partner: the EHR giant now contributes cohorts of millions of behavioral-health patients and related de-identified data into NeuroBlu, aiming at a single source of truth for behavioral-health evidence.